HBI Deals+Insights / News
Lab group Synlab has announced pricing at the bottom of its range, a price that values the group at just 8.8 times 2020 EBITDA. Sources say that investors are worried about the resilience and performance of its huge COVID earnings. The IPO is now proceeding at a valuation far lower than that generated by the sale of Cerba to EQT.